CorMedix Inc., of Bridgewater, N.J., is requesting a pre-investigational new drug meeting with the FDA to discuss next steps for Neutrolin, which is being developed for the prevention of catheter-related bloodstream infections and maintenance of catheter patency in tunneled, cuffed, central venous catheters used for vascular access in hemodialysis patients.